<DOC>
	<DOCNO>NCT00455442</DOCNO>
	<brief_summary>This two-week study test efficacy safety mifepristone prevention olanzapine-induced weight gain healthy male volunteer measure change body weight BMI .</brief_summary>
	<brief_title>A Two-Week Study Efficacy Safety Mifepristone Prevention Olanzapine-Induced Weight Gain</brief_title>
	<detailed_description />
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Healthy male volunteer 18 40 year age BMI ≥ 18 ≤ 25 Able provide write informed consent Routine clinical laboratory test either within normal limit clinically meaningful outside normal limit History Cushing 's syndrome Addison 's disease Prior current history psychiatric disorder , include eat disorder anorexia nervosa , bulimia nervosa , bingeeating disorder Positive urine drug screen nonprescribed drug abuse ( include limit amphetamine , cannabinoids , barbiturate , cocaine , opiates , benzodiazepine ) Participation clinical investigation drug , biological investigational therapy within 30 day prior dose Have history allergic reaction either mifepristone olanzapine Any clinically significant abnormality screen laboratory test QTc Bazzett 's ≥ 450 msec Any major medical condition , opinion Investigator would place patient undue risk . Receiving prescription overthecounter medication could potentially affect appetite weight History recent ( within 6 month screen ) significant weight fluctuation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>